- Healthcare 150
- Posts
- AI Is Making Healthcare Easier to Build and Harder to Defend
AI Is Making Healthcare Easier to Build and Harder to Defend
Digital health funding rebounds, Samsung Biologics makes a $1.8B peptide bet, and India looks to become a global healthcare innovation engine.
Good morning, ! Today we look at how healthcare capital is becoming more concentrated and more selective—from AI-driven digital health funding and the growing importance of defensible moats to Samsung Biologics’ $1.8B bet on peptides and India’s push to become a global healthcare innovation hub.
As capital increasingly follows strategic assets, proprietary capabilities and critical infrastructure, the biggest opportunities may belong to the companies building what healthcare cannot easily replicate.
Know someone in the healthcare space who should see this? Forward it their way. Here’s the link.
Join PE150 and Caplink for our AI & Data Insight Breakfast in London. Register here.
— The Healthcare150 Team
MICROSURVEY
What most prevents digital health companies from reaching enterprise scale? |
You’re invited: Where AI Meets Private Equity
Artificial intelligence has moved beyond experimentation. The real question for private equity firms is no longer whether to adopt AI, but how to turn it into measurable value across the investment lifecycle.
On November 18, PE150 and CapLink Group will host the AI / Data & Insight Private Capital Breakfast, an invitation-only gathering at London's May Fair Hotel that will bring together operating partners, deal teams, portfolio executives, and technology leaders to discuss what AI adoption actually looks like inside private equity.
The morning will feature three practitioner-led discussions:
AI Into Value Creation — How leading firms are transforming AI from dashboards into repeatable value creation playbooks across portfolio companies. Sponsored by Exact Insight.
AI Across the Investment Lifecycle — Practical applications spanning sourcing, due diligence, investment decisions, and portfolio management.
Building the AI-Enabled Private Equity Firm — The operating models, data strategies, and organizational capabilities required to scale AI successfully.
Interested in attending? Register or request the full agenda here.
Interested in sponsoring? Email [email protected]
HEADLINE OF THE WEEK
AI Is Raising Capital. Moats Are Getting Harder.
Digital health funding reached $7.4B in H1 2026, up $1B year over year, but the rebound is increasingly concentrated. Just 20 megadeals across 19 companies captured 45% of all capital deployed, meaning roughly 8% of deals absorbed nearly half of funding.
AI is driving the reset, but not because investors simply want more AI exposure. As foundation models make software cheaper and easier to build, technical differentiation is becoming less durable. The premium is shifting toward assets AI cannot easily replicate: deep domain expertise, ownership of broader clinical and administrative workflows, embedded service capabilities, and trusted partnerships.
The same logic is appearing in consolidation. Digital health recorded 115 acquisitions in H1 2026, with revenue cycle management emerging as an active consolidation target.
Why it matters: The AI boom is raising the bar for defensibility. For investors and operators, the strongest digital health platforms may increasingly be those that control workflows, distribution, data, and customer relationships, not those with the newest model.
Bottom line: AI is making digital health easier to build, but harder to defend. (More)
DEAL OF THE WEEK
Samsung Biologics Bets $1.8B on the Peptide Economy
Samsung Biologics launched a $1.8B all-cash tender offer for Swiss peptide CDMO PolyPeptide Group at a 40% premium, making it the largest biopharma M&A deal in Korean history.
The acquisition expands Samsung Biologics into peptide therapeutics—including the rapidly growing GLP-1 market—and gives the company a new foothold in a critical part of the pharmaceutical supply chain.
Why it matters: The deal is another sign that pharma infrastructure is becoming as strategically valuable as the drugs themselves. As demand for GLP-1 therapies continues to grow, manufacturers with specialized peptide capabilities are becoming increasingly attractive acquisition targets.
HEALTHCARE DEAL TRACKER
$4.1B | Catalyst Pharmaceuticals → Angelini Pharma
Angelini completed its acquisition of rare-disease drugmaker Catalyst Pharmaceuticals, backed by $2B in equity financing from Blackstone and Italy’s CDP. Catalyst has now been delisted from Nasdaq. Read more
~$1.5B | Personalis → Tempus AI
Tempus agreed to acquire Personalis in an all-stock transaction, adding MRD cancer testing to its AI-powered precision oncology platform. Read more
$650M | SPR Therapeutics → Medtronic
Medtronic completed its acquisition of SPR Therapeutics, adding a minimally invasive, non-opioid treatment for chronic and acute pain to its portfolio. Read more
$437M | Cross Country Healthcare → Knox Lane
Knox Lane completed its take-private of the 7th-largest U.S. healthcare staffing company. The deal also includes the separation of its locums business into Knox Lane portfolio company All Star Healthcare Solutions. Read more
Also worth watching: Cardinal Health’s $360M pair of home-care acquisitions and Ipsen’s acquisition of Memo Therapeutics for €200M upfront plus milestones exceeding €700M.
REGIONAL FOCUS
India’s Next Healthcare Export: Science
India’s healthcare investment story is entering a new phase. For years, the country’s advantage was primarily about scale: generic drugs, vaccines, biosimilars and cost-efficient manufacturing. The next opportunity is more ambitious — turning that industrial base into a deeper innovation engine.
Over the past five years, oncology and hematology captured 28% of PE/VC capital deployed across therapeutic areas, followed by infectious diseases at 15%. Together, the two categories attracted 43% of investment, highlighting where investors see the strongest combination of unmet need, scientific potential and commercial opportunity.
The shift matters. India is no longer competing only on the cost of producing healthcare products. It is increasingly trying to capture value earlier in the innovation chain — from research and drug discovery to advanced therapies and clinical development.
The investment thesis is straightforward: India already has the scale. The question is whether it can convert that scale into globally competitive science.
For investors, that transition could create the next generation of healthcare platforms. For incumbents, it may create a new source of competition — and potential acquisition targets.
Bottom line: India’s healthcare opportunity is moving from “build cheaper” to “invent better.”
